Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Baldini

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Hematological Oncology|February 7, 2019
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical networkSara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 12, 2022
Clinical features of type 1 and 2 refractory celiac disease: Results from a large cohort over a decadeLuca Elli, Pietro Soru, Leda Roncoroni, et al.
British Journal of Haematology|March 23, 2011
Integrated profiling of diffuse large B-cell lymphoma with 7q gainEkaterina Chigrinova, Michael Mian, Yulei Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Leukemia & Lymphoma|February 28, 2007
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patientsSamantha Pozzi, Raffaella Marcheselli, Stefano Sacchi, et al.
Blood|September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Microbiology Spectrum|September 1, 2021
Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in ItalyElisa Saccon, Alessandra Bandera, Mariarita Sciumè, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete ResponseRoberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
Blood|October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive programMarco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Hematological Oncology|February 7, 2019
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical networkSara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 12, 2022
Clinical features of type 1 and 2 refractory celiac disease: Results from a large cohort over a decadeLuca Elli, Pietro Soru, Leda Roncoroni, et al.
British Journal of Haematology|March 23, 2011
Integrated profiling of diffuse large B-cell lymphoma with 7q gainEkaterina Chigrinova, Michael Mian, Yulei Shen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Leukemia & Lymphoma|February 28, 2007
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patientsSamantha Pozzi, Raffaella Marcheselli, Stefano Sacchi, et al.
Blood|September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Microbiology Spectrum|September 1, 2021
Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in ItalyElisa Saccon, Alessandra Bandera, Mariarita Sciumè, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2018
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete ResponseRoberto Mina, Maria Teresa Petrucci, Paolo Corradini, et al.
Blood|October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive programMarco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
Pageof 16